Indeed, previous studies have reported that anti-PD-L1 therapy could reshape metabolic pathways in the tumor microenvironment and re-stimulate exhausted CD8+ T cells for cytotoxicity [192]. The gene discussed is CD8A; the disease is neoplasm.